Inspra
Product Images NDC 21695-797

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Inspra (NDC 21695-797). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (C7bc9486 8e61 4ba1 827f 2cd8c304b454 01)

Chemical structure diagram of eplerenone, the active ingredient in Inspra, showing its steroidal skeleton with various functional groups including ketones and an ester.*

FDA Label Image

Figure (C7bc9486 8e61 4ba1 827f 2cd8c304b454 02)

A line graph showing cumulative incidence (%) over time (months since randomization) comparing Inspra and placebo groups. The graph includes risk numbers at various time points and statistical data indicating a significant difference between groups.*

FDA Label Image

Figure (C7bc9486 8e61 4ba1 827f 2cd8c304b454 03)

A chart depicting overall mortality rates comparing Eplerenone versus Placebo, stratified by age groups (<65, 65-75, ≥75 years), gender (female, male), and race (Non-Caucasian, Caucasian). It presents total number of events and patients with a hazard ratio scale indicating relative outcomes between Eplerenone and Placebo.*

FDA Label Image

Figure (C7bc9486 8e61 4ba1 827f 2cd8c304b454 04)

A forest plot chart showing hazard ratios comparing spironolactone versus placebo impact on overall mortality. The chart categorizes data by diabetes status, hypertension history, and Killip class, displaying total events and patients for each subgroup with confidence intervals around hazard ratios.*

FDA Label Image

Figure (C7bc9486 8e61 4ba1 827f 2cd8c304b454 05)

A forest plot chart showing hazard ratios with 95% confidence intervals for overall mortality events in patients grouped by creatinine clearance levels. It compares the effectiveness of eplerenone versus placebo across four creatinine clearance subgroups, indicating the number of events and patients within each group.*

FDA Label Image

Figure (C7bc9486 8e61 4ba1 827f 2cd8c304b454 06)

A forest plot chart showing hazard ratios with 95% confidence intervals for overall mortality and subgroups based on baseline use of beta blockers, ACE inhibitors, digoxin, and diuretics. The chart compares the effects of eplerenone versus placebo, with numerical data for total events and total patients in each subgroup.*

FDA Label Image

Figure (C7bc9486 8e61 4ba1 827f 2cd8c304b454 07)

A dose response chart titled 'INSPRA Dose Response - Trough Cuff SBP Placebo-Subtracted Adjusted Mean Change from Baseline in Hypertension Studies' showing the reduction in SBP (mm Hg) on the y-axis and INSPRA dose (mg/day) on the x-axis. Data points are differentiated by study and dosing regimen including Study 1 QD, Study 2 QD, and Study 2 BID.*

FDA Label Image

Figure (C7bc9486 8e61 4ba1 827f 2cd8c304b454 08)

A scatter plot showing the dose response of Inspra (mg/day) on the reduction in diastolic blood pressure (DBP) measured in mmHg. The graph compares adjusted mean changes from baseline in hypertension studies, including data points for Study 1 QD, Study 2 QD, and Study 2 BID, with Inspra doses ranging from about 25 to 200 mg/day.*

FDA Label Image

Logo (C7bc9486 8e61 4ba1 827f 2cd8c304b454 09)

FDA Label Image

Inspra 25mg (C7bc9486 8e61 4ba1 827f 2cd8c304b454 10)

Inspra 25mg tablet label shows 90 tablets per bottle with each tablet containing 25mg Eplerenone. The label includes NDC 21695-797-90 and indicates prescription-only status. Distributed by Physician Partner, Thousand Oaks, CA. The label also includes storage instructions and product identification number RI079790.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.